Johnson & Johnson Buys Auris Health for $3.4 Billion to Expand Robotic Surgery
Johnson & Johnson's Ethicon division acquires robotic surgery startup Auris Health for $3.4 billion in cash to enhance its lung cancer diagnostics and treatment capabilities.
Johnson & Johnson's medical device division, Ethicon, spends $3.4 billion in cash to acquire Auris Health, a developer of robotic diagnostics and surgical devices focused on lung cancer. The healthcare giant states that an additional $2.35 billion in payouts is possible if Auris achieves specific future milestones. This acquisition provides a massive return for investors like Lux Capital and Coatue Management, which participated in a $280 million funding round just two years ago.
Auris Health operates under the leadership of serial entrepreneur Fred Moll, who previously co-founded the highly successful robotic surgical systems manufacturer Intuitive Surgical. The company recently gains FDA approval for its Monarch platform, which utilizes a flexible robotic endoscope to reach difficult areas inside the human body. Doctors use video game-style controllers and 3D models to navigate the system, allowing for a less invasive and more accurate way to biopsy lung lesions that are typically hard to reach with manual techniques.
The Monarch platform directly addresses a major challenge in early-stage lung cancer diagnosis, where traditional manual biopsies fail to provide a diagnosis 40 percent of the time. By making these diagnostic procedures less traumatic and more systematic, the technology enables clinicians to identify and treat cancer much earlier. Johnson & Johnson executives emphasize that combining Auris's advanced robotics with their own instrumentation and connectivity will make surgery safer, drive efficiency, and ultimately improve patient outcomes.